Form 4 for VERA Vera Therapeutics, Inc.
Accepted 2025-02-20 00:00:00 ET · period of report 2025-02-18 · accession 0001415889-25-004849 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-20 | 2025-02-18 | VERA | Turner William D. | Chief Development Off | A - Grant | $0.00 | +22.5K | 22.5K | New | $0 |
| D | 2025-02-20 | 2025-02-18 | VERA | Turner William D. | Chief Development Off | A - Grant | $0.00 | +45.0K | 45.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-02-18 | A | A | 22,500 | $0.00 | 22,500 | D | — | — | (F1) Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2021 Equity Incentive Plan. One-fourth of the RSUs, rounded to the nearest whole share, vest on each of February 20, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service through each vesting date. |
| 2 | Derivative | Stock Option (right to buy) | 2025-02-18 | A | A | 45,000 | $0.00 | 45,000 | D | $29.18 · — to 2035-02-17 | 45,000 Class A Common Stock | (F2) 1/48 of the shares subject to the stock option will vest and become exercisable on March 18, 2025, and 1/48th of the shares subject to the stock option will vest and become exercisable monthly on the same day of each month thereafter, subject to the Reporting Person's continuous service through each vesting date. |